Insmed Incorporated
HealthcareNASDAQ:INSM · NASDAQ Global Select
+$1.39 today
Vol 2.93M · Avg 3.15M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$819.6M of revenue converted into -$1.2B of net income for the selected period. Gross margin is 80.1% and net margin is -184.3%, showing how much revenue survives after costs and taxes. EPS is $-5.75, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $606.4M +66.7% | $363.7M +19.2% | $305.2M +24.4% | $245.4M +30.2% | $188.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $124.9M +45.6% | $85.7M +30.8% | $65.6M +19.0% | $55.1M +24.9% | $44.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $481.5M +73.2% | $278.0M +16.0% | $239.6M +26.0% | $190.2M +31.8% | $144.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 79.4% +3.0pp | 76.4% -2.1pp | 78.5% +1.0pp | 77.5% +1.0pp | 76.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $771.1M +28.9% | $598.4M +4.8% | $571.0M +43.6% | $397.5M +45.7% | $272.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $701.2M +52.1% | $461.1M +33.9% | $344.5M +29.6% | $265.8M +13.5% | $234.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.7B +43.4% | $1.2B +21.8% | $949.3M +46.6% | $647.6M +24.7% | $519.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $16.4M +49.4% | $11.0M +4.1% | $10.6M +2.4% | $10.3M -27.2% | $14.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$1.2B -43.1% | -$818.8M -24.0% | -$660.2M -47.6% | -$447.4M -16.6% | -$383.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -193.2% +31.9pp | -225.1% -8.8pp | -216.3% -34.0pp | -182.3% +21.2pp | -203.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.2B -34.0% | -$878.3M -23.8% | -$709.6M -55.2% | -$457.3M -21.9% | -$375.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -194.0% +47.4pp | -241.5% -9.0pp | -232.5% -46.1pp | -186.4% +12.6pp | -199.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $60.7M +13.8% | $53.3M +26.5% | $42.1M +280.2% | $11.1M +6268.4% | $174.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $83.8M -1.3% | $84.9M +3.9% | $81.7M +208.9% | $26.4M -34.7% | $40.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$95.0M -198.7% | -$31.8M +14.9% | -$37.4M -63.8% | -$22.8M +62.8% | -$61.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.3B -39.7% | -$910.1M -21.8% | -$747.0M -55.6% | -$480.2M -10.0% | -$436.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -209.7% +40.5pp | -250.2% -5.5pp | -244.8% -49.1pp | -195.7% +35.9pp | -231.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.0M +35.6% | $3.7M +45.1% | $2.6M +84.7% | $1.4M +178.7% | -$1.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.3B -39.7% | -$913.8M -21.9% | -$749.6M -55.7% | -$481.5M -10.8% | -$434.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -210.5% +40.7pp | -251.2% -5.6pp | -245.6% -49.3pp | -196.3% +34.4pp | -230.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -15.1% | -$6 -4.3% | -$5 -36.6% | -$4 -0.8% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -15.1% | -$6 -4.3% | -$5 -36.6% | -$4 -0.8% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $213.6M +30.2% | $164.0M +16.8% | $140.4M +14.1% | $123.0M +9.7% | $112.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $213.6M +30.2% | $164.0M +16.8% | $140.4M +14.1% | $123.0M +9.7% | $112.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.51B
Takeda Pharmaceutical Company Limited
NYSE:TAK
$50.48B
Humana Inc.
NYSE:HUM
$45.30B
Haleon plc
NYSE:HLN
$40.37B
Agilent Technologies, Inc.
NYSE:A
$36.53B
Alcon Inc.
NYSE:ALC
$32.53B
IQVIA Holdings Inc.
NYSE:IQV
$29.94B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.60B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.29B
ResMed Inc.
NYSE:RMD
$28.10B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INSM generate?
Insmed Incorporated (INSM) reported $606.42M of revenue in fiscal 2025.
Is INSM profitable?
Insmed Incorporated (INSM) reported -$1,276,775,000.00 of net income, with a net margin of -210.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.